Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2020
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung CancerSonia Singh, Adnan A Jaigirdar, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic TherapyRobert Q Le, Kamar Godder, Jingyan Wang, et al.
Journal of Comparative Effectiveness Research|March 12, 2026
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano studyRichard Scott Swain, Andrew Klink, Parisa Asgarisabet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast CancerSakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2021
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in OncologyJulie A Schneider, Yutao Gong, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2022
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic TherapyDonna Przepiorka, Robert Q Le, Alexei Ionan, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2020
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung CancerSonia Singh, Adnan A Jaigirdar, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic TherapyRobert Q Le, Kamar Godder, Jingyan Wang, et al.
Journal of Comparative Effectiveness Research|March 12, 2026
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano studyRichard Scott Swain, Andrew Klink, Parisa Asgarisabet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast CancerSakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2021
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in OncologyJulie A Schneider, Yutao Gong, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2022
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic TherapyDonna Przepiorka, Robert Q Le, Alexei Ionan, et al.
Pageof 11